Management of Urologic Cancers

tibbi onkoloji ozel 13-4 kapak

Zeki Gökhan SÜRMELİa, Çağatay ARSLANb

aBahreyn Onkoloji Merkezi, BAHREYN
bBahçeşehir Üniversitesi Tıp Fakültesi, Tıbbi Onkoloji BD, İstanbul, TÜRKİYE

ABSTRACT
The incidence of prostate, bladder and kidney cancers increase with age and these malignancies are most commonly diagnosed among older adults. These cancers usually impair the quality of life, limit the functional capacity and decrease the life expectancy of elderly people. Age-related physiological changes and comorbidities can increase the risk of treatment-related toxicities, while decreasing the treatment efficacy. Functional and cognitive status, quality of life, patient preferences and expected survival benefit should be considered in treatment decisions. Therefore, elderly patients with urological cancers should be managed after multidisciplinary assessment. In this section, we summarized the treatment options in older adults with prostate, bladder and kidney cancers.
Keywords: Elderly; urology; bladder; kidney; prostate

Referanslar

  1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394- 424. [Crossref]  [PubMed]
  2. Hacıkamiloğlu E, Gültekin M, Boztaş G, Dündar S, utku E, Ergün A, et al. Türkiye Kanser İstatistikleri. Ankara: T.C. Sağlık Bakanlığı, Türkiye Halk Sağlığı Kurumu.;2017.
  3. Droz JP, Albrand G, Gillessen S, Hughes S, Mottet N, Oudard S, et al. Management of Prostate Cancer in Elderly Patients: Recommendations of a Task Force of the International Society of Geriatric Oncology. Eur urol. 2017;72(4):521-31. [Crossref]  [PubMed]
  4. Mottet N, Bellmunt J, Representative EBP, Bolla M, Bourke L, vice-chair PC, et al. Prostate Cancer EAu Guidelines 2017. European urology. 2017.
  5. Hamdy FC, Donovan JL, Lane JA, Mason M, Metcalfe C, Holding P, et al. 10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer. N Engl J Med. 2016;375(15):1415-24. [Crossref]  [PubMed]
  6. NCCN Clinical Practice Guidelines in Oncology, Prostate Cancer, version 1.2019-March 6, 2019.
  7. James ND, Sydes MR, Clarke NW, Mason MD, Dearnaley DP, Spears MR, et al. Addition of docetaxel, zoledronic acid, or both to firstline long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet. 2016;387(10024):1163-77. [Crossref]  [PubMed]
  8. Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M, et al. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. N Engl J Med. 2015;373(8):737-46. [Crossref]  [PubMed]  [PMC]
  9. Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY, et al. Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer. N Engl J Med. 2017;377(4):352-60. [Crossref]  [PubMed]
  10. James ND, de Bono JS, Spears MR, Clarke NW, Mason MD, Dearnaley DP, et al. Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy. N Engl J Med. 2017;377(4):338-51. [Crossref]  [PubMed]  [PMC]
  11. Beer TM, Armstrong AJ, Rathkopf D, Loriot Y, Sternberg CN, Higano CS, et al. Enzalutamide in Men with Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREvAIL Study. Eur urol. 2017;71(2):151-4. [Crossref]  [PubMed]  [PMC]
  12. Ryan CJ, Smith MR, Fizazi K, Saad F, Mulders PF, Sternberg CN, et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COu-AA-302): final overall survival analysis of a randomised, double-blind, placebocontrolled phase 3 study. Lancet Oncol. 2015; 16(2):152-60. [Crossref]  [PubMed]
  13. de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010;376(9747):1147- 54. [Crossref]  [PubMed]
  14. Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367(13): 1187-97. [Crossref]  [PubMed]
  15. Fizazi K, Scher HI, Molina A, Logothetis CJ, Chi KN, Jones RJ, et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COu-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2012;13(10):983-92. [Crossref]  [PubMed]
  16. Parker C, Nilsson S, Heinrich D, Helle SI, O'- Sullivan JM, Fossa SD, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369(3):213-23. [Crossref]  [PubMed]
  17. National Cancer Institute, Surveillance, Epidemiology, and End Results Program, Cancer Stat Facts: Bladder Cancer. Available from: Erişim tarihi: 09/03/2019. [Link]
  18. Babjuk M, Bohle A, Burger M, Capoun O, Cohen D, Comperat EM, et al. EAu Guidelines on Non-Muscle-invasive urothelial Carcinoma of the Bladder: update 2016. Eur urol. 2017;71(3):447-61. [Crossref]  [PubMed]
  19. NCCN Clinical Practice Guidelines in Oncology, Bladder Cancer, version 1.2019-December 20,2018.
  20. Alfred Witjes J, Lebret T, Comperat EM, Cowan NC, De Santis M, Bruins HM, et al. updated 2016 EAu Guidelines on Muscle-invasive and Metastatic Bladder Cancer. Eur urol. 2017;71(3):462-75. [Crossref]  [PubMed]
  21. Galsky MD, Hahn NM, Rosenberg J, Sonpavde G, Hutson T, Oh WK, et al. Treatment of patients with metastatic urothelial cancer "unfit" for Cisplatin-based chemotherapy. J Clin Oncol. 2011;29(17):2432-8. [Crossref]  [PubMed]
  22. Necchi A, Anichini A, Raggi D, Briganti A, Massa S, Luciano R, et al. Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive urothelial Bladder Carcinoma (PuRE-01): An Open-Label, Single-Arm, Phase II Study. J Clin Oncol. 2018:JCO1801148. Epub 2018/10/23. [Crossref]  [PubMed]
  23. Balar Av, Castellano D, O'Donnell PH, Grivas P, vuky J, Powles T, et al. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study. Lancet Oncol. 2017;18(11):1483-92. [Crossref]  [PubMed]
  24. Balar Av, Galsky MD, Rosenberg JE, Powles T, Petrylak DP, Bellmunt J, et al. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet. 2017;389(10064):67- 76. [Crossref]  [PubMed]
  25. Bellmunt J, de Wit R, vaughn DJ, Fradet Y, Lee JL, Fong L, et al. Pembrolizumab as Second-Line Therapy for Advanced urothelial Carcinoma. N Engl J Med. 2017;376(11): 1015-26. [Crossref]  [PubMed]  [PMC]
  26. Powles T, Duran I, van der Heijden MS, Loriot Y, vogelzang NJ, De Giorgi u, et al. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2018;391(10122):748- 57. [Crossref]  [PubMed]
  27. National Cancer Institute, Surveillance, Epidemiology, and End Results Program, Cancer Stat Facts: Kidney and Renal Pelvis Cancer.
  28. NCCN Clinical Practice Guidelines in Oncology, Kidney Cancer, version 3.2019-February 6,2019.
  29. Ljungberg B, Albiges L, Abu-Ghanem Y, Bensalah K, Dabestani S, Montes SF, et al. European Association of urology Guidelines on Renal Cell Carcinoma: The 2019 update. Eur urol. 2019. Epub 2019/02/26. [Crossref]  [PubMed]
  30. Escudier B, Porta C, Schmidinger M, RiouxLeclercq N, Bex A, Khoo v, et al. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019. Epub 2019/02/23. [Crossref]  [PubMed]
  31. Rini BI, Plimack ER, Stus v, Gafanov R, Hawkins R, Nosov D, et al. Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med. 2019. Epub 2019/02/20. [Crossref]  [PubMed]
  32. Kanesvaran R, Le Saux O, Motzer R, Choueiri TK, Scotte F, Bellmunt J, et al. Elderly patients with metastatic renal cell carcinoma: position paper from the International Society of Geriatric Oncology. Lancet Oncol. 2018;19(6): e317-e26. [Crossref]  [PubMed]